South Korea Approves Novartis Banrapia for Kidney Disease IgAN: First Country Outside US
· techtimes.com · popularity 17/100 · 0 similar stories today · Medicine & Clinical Health (Health & Life Sciences)
Read the original at techtimes.com →
Summary
Vanrafia (atrasentan) wins MFDS approval in South Korea for IgA nephropathy, making Korea the first country outside the US to clear a selective ET-A receptor antagonist for kidney disease. Approved via GIFT fast-track designation #53, Novartis's oral drug reduced proteinuria 36.1% in the Phase III ALIGN trial. HIRA reimbursement review is pending.
Found in: Tech Times. Rating basis: single outlet; outlet tier 2 (unlisted); 1 feeds; feed position 15.